OTC Stockz
No Result
View All Result
Sunday, March 26, 2023
  • Login
  • Home
  • OTC Stocks
  • Micro Caps
  • Stocks
  • Cryptocurrency
  • NFTs
  • Education
  • Home
  • OTC Stocks
  • Micro Caps
  • Stocks
  • Cryptocurrency
  • NFTs
  • Education
OTC Stockz
No Result
View All Result
Home Micro Caps

Roche’s Alzheimer’s Flop Trial Removes One Competitor, But Reimbursement Debate Lingers – Eisai Co (OTC:ESALY), Roche Holding (OTC:RHHBF), Roche Holding (OTC:RHHVF), Roche Holding (OTC:RHHBY), Eisai Co (OTC:ESALF), Biogen (NASDAQ:BIIB)

by OTC Stockz
November 14, 2022
in Micro Caps
Reading Time: 2 mins read
0 0
A A
0
Roche’s Alzheimer’s Flop Trial Removes One Competitor, But Reimbursement Debate Lingers – Eisai Co (OTC:ESALY), Roche Holding (OTC:RHHBF), Roche Holding (OTC:RHHVF), Roche Holding (OTC:RHHBY), Eisai Co (OTC:ESALF), Biogen (NASDAQ:BIIB)
Share on FacebookShare on Twitter




Earlier today, MorphoSys AG MOR and its partner Roche Holdings AG RHHBY reported disappointing results from gantenerumab studies in mild cognitive impairment (MCI) due to Alzheimer’s and mild Alzheimer’s dementia.
Needham writes that with both GRADUATE studies failing to meet the primary endpoint, it removes a potential competitor for Eisai Ltd ESALY and Biogen Inc’s BIIB lecanemab. 
Roche’s data was much awaited after Biogen and Eisai said the global Phase 3 confirmatory study, “Clarity AD,” of lecanemab met the primary endpoint and all key secondary endpoints with highly statistically significant results. 
However, heading into 2023, the ability of Eisai/BIIB to persuade CMS to reconsider the current National coverage determinations (NCD) and secure full reimbursement for lecanemab is the biggest debate on the stock. 
The recently released data, both Eisai and Biogen, have postured greater confidence that the CLARITY results can be sufficient for reconsideration. 
At face value, CMS’s bar for clinically meaningful evidence is high. It will look across the entire Aβ class for clinical evidence, which may require positive evidence across multiple Aβ products, and for which today’s results are on gantenerumab only serve to complicate the body of evidence. 
Regarding the next data readouts, Needham looks for any incremental details at CTAD for lecanemab (Nov. 29) and gantenerumab (Nov. 30).
Price Action: BIIB shares are up 4.84% at $303.47 on the last check Monday.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.



Source link

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

No Result
View All Result
  • Trending
  • Comments
  • Latest
Over the counter stocks (OTC Stock)

The role of market makers in over the counter stocks (OTC Stocks)

March 6, 2023
5 Common Mistakes to Avoid When Investing in Over the Counter (OTC) Stocks

5 Common Mistakes to Avoid When Investing in Over the Counter (OTC) Stocks

February 27, 2023
Why Are Stocks Down Today?

The Future of OTC Stocks: Navigating the Changing Landscape of Over-the-Counter Investments

February 13, 2023
Over the counter stocks (OTC Stock)

The Benefits of Investing in Over-The-Counter (OTC) Stocks

February 10, 2023
Over the counter stocks (OTC Stock)

Breaking Down the World of Over-the-Counter Stocks (OTC Stock): A Comprehensive Guide

February 10, 2023
In the penny stock market, Xcelerate, Inc. (OTC: XCRT) is emerging as a top Healthcare Services stock to watch in 2022. 

Fabian Urquijo Joins the Advisory Board of Xcelerate, Inc. (OTCMKT: XCRT)

February 2, 2023
OTC Markets Group Welcomes M.O.B.A. Network to OTCQX

Drive Shack Inc. Joins the OTCQX Best Market

January 31, 2023
New York Considers Bill to Establish Cryptocurrency as a Form of Payment for State Agencies

New York Considers Bill to Establish Cryptocurrency as a Form of Payment for State Agencies

January 30, 2023
OTC Stockz

Get the latest news and follow the coverage of OTC Stocks, Micro Caps, Cryptocurrency, NFTs and more from the top trusted sources.

CATEGORIES

  • Cryptocurrency
  • Micro Caps
  • NFTs
  • OTC Stocks
  • Stock Market
  • Stock Market Education
  • Trending
  • Writers Analysis

LATEST UPDATES

  • The role of market makers in over the counter stocks (OTC Stocks)
  • 5 Common Mistakes to Avoid When Investing in Over the Counter (OTC) Stocks
  • Home
  • Disclaimer
  • Privacy Policy
  • DMCA
  • Cookie Privacy Policy
  • Terms and Conditions
  • Contact us

Copyright © 2022 OTC Stockz.
OTC Stockz is not responsible for the content of external sites.

No Result
View All Result
  • Home
  • OTC Stocks
  • Micro Caps
  • Stocks
  • Cryptocurrency
  • NFTs
  • Education

Copyright © 2022 OTC Stockz.
OTC Stockz is not responsible for the content of external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Verified by MonsterInsights